Adjuvant Intraperitoneal Gemcitabine for Resectable Pancreatic Adenocarcinoma

Summary

This is a phase II study evaluating the use of intraperitoneal gemcitabine given intraoperatively and as adjuvant therapy for patients with resectable pancreas cancer. The primary objective of this study is to evaluate the overall safety of intraperitoneal gemcitabine given intraoperatively and postoperatively for adjuvant treatment of resectable pancreatic adenocarcinoma. The secondary objectives are to evaluate the efficacy of this treatment regimen as reflected in overall survival at 2-years, to study the patterns of disease recurrence following this treatment, to study the pharmacology of intraperitoneal gemcitabine and to study changes in peritoneal cytology with pancreatic cancer resection.

Timeline

Start

2010-08

Primary completion

2014-02

Completion

2014-02

Outcome

Outcome not reported

Stopped: “Study suspended”

Drugs

Indications